McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
McKesson (MCK) came out with quarterly earnings of $7.07 per share, beating the Zacks Consensus Estimate of $6.89 per share. This compares to earnings of $6.23 per share a year ago.
Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S. pharmaceuticals segment on robust demand for specialty and branded drugs.
MCK's second-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Beyond analysts' top -and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, McKesson (MCK) closed at $508.95, marking a +0.3% move from the previous day.
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In the latest trading session, McKesson (MCK) closed at $513.67, marking a +0.86% move from the previous day.
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.